Alimera Sciences

Committee Composition

  Audit Nominating and Governance Compensation
Dr. Glen Bradley, Ph.D. Independent Director Member of Audit Committee    
Consultant and advisor for ophthalmic and non-ophthalmic medical device companies

Dr. Bradley has been a member of our board of directors since 2011. Dr. Bradley serves as a consultant and advisor for ophthalmic and non-ophthalmic medical device companies. A veteran of the eye care industry, Dr. Bradley served as an executive officer of Novartis, AG of Basel, Switzerland from 1996 to 2003. In addition, he was the chief executive officer of CIBA Vision Group in Atlanta and Zurich from 1990 to 2003. Prior to this, he led CIBA Vision Corporation in Atlanta as president and chief executive officer from 1986-1989. Early in his career, Dr. Bradley worked for several different divisions of the CIBA-Geigy Corporation.

Dr. Bradley earned a Bachelor of Science degree in chemical engineering from Mississippi State University, a Ph.D. in chemical engineering from Louisiana State University, an M.B.A. in business and finance from the University of Connecticut and is a graduate of the Advanced Management Program at Harvard Business School.


Mark J. Brooks, M.B.A. Independent Director Member of Audit Committee   Member of Compensation Committee
Managing Director, Scale Venture Partners

Mark Brooks has been a member of our board of directors since 2004. Since its formation in January 2007, Mr. Brooks has served as a managing director of Scale Venture Partners. Prior to joining Scale Venture Partners, from 1995 Mr. Brooks worked for Bank of America Ventures, ultimately serving as a Managing Director. Mr. Brooks also serves on the board of directors of IPC The Hospitalist Company, Inc., a publicly traded provider of hospitalist services, and also serves on the board of five privately held companies: National Healing Corporation, LivHome, Inc., New Century Hospice, Inc. Spinal Kinetics, Inc., and Oraya Therapeutics, Inc. Mr. Brooks holds an M.B.A. from the Wharton School at the University of Pennsylvania and a B.A. in Economics from Dartmouth College.


Brian Halak, Ph.D., B.S.E. Independent Director   Member of Nominating and Governance Committee Committee Chair for Compensation Committee
Partner at Domain Associates, L.L.C.

Dr. Halek has been a member of our board of directors since 2004. Dr. Halak joined Domain Associates, L.L.C. in 2001 and has served as a Partner of Domain Associates, L.L.C. since 2006. Prior to joining Domain Associates, L.L.C., Dr. Halak served as an analyst of Advanced Technology Ventures from 2000 to 2001. From 1993 to 1995, Dr. Halak has served as an analyst of Wilkerson Group. Dr. Halak holds a Doctorate in Immunology from Thomas Jefferson University and a B.S. in Engineering from the University of Pennsylvania. Dr. Halak has served on the board of directors of more than 10 emerging companies in the life sciences industry in the past 10 years, including Dicerna Pharmaceuticals, Inc., which completed a public offering on Nasdaq in 2014,Vanda Pharmaceuticals, Inc., a public company listed on Nasdaq, and Esprit Pharma, Inc., a company that was acquired by Allergan, Inc.


Garheng Kong, M.D., Ph.D. Independent Director     Member of Compensation Committee
Managing Partner, HealthQuest Capital

Dr. Kong has been a member of our board of directors since 2012. Dr. Kong is the Managing Partner of HealthQuest Capital, a healthcare-focused investment firm, and was previously a general partner at Sofinnova Ventures, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong spent time at GlaxoSmithKline, McKinsey & Company, and TherOx. Dr. Kong has served on the board of directors of Histogenics Corporation, a publicly traded biotechnology company where he also serves as the Chairman of the board, since 2012. Since November 2008, Dr. Kong has been the Chairman of the board of Cempra Pharmaceuticals, where he has been a board member since September 2006. Dr. Kong has also been on the board of LabCorp since December 2013 and sits on the Duke University Medical Center Board of Visitors. Dr. Kong holds an M.D., Ph.D. in Biomedical Engineering and an M.B.A. from Duke University.


James R. Largent Chairman of the Board Independent Director   Committee Chair for Nominating and Governance Committee Member of Compensation Committee
Chairman of the Board

James Largent has been a member of our board of directors since 2011 and became our Chairman in 2015. Mr. Largent has worked extensively within the medical industry. Mr. Largent most recently served as a medical and pharmaceutical consultant, including work with U.S. ophthalmic device company, Eyeonics Inc. While there, he led the lobbying effort that resulted in the 2005 landmark decision by the Centers for Medicare & Medicaid Services (CMS) to allow for patient shared billing for premium presbyopia-correcting intraocular lenses. Also in his role as a consultant, he assisted a multinational pharmaceutical and medical device company in the evaluation of strategic targets. Prior to this, Mr. Largent served in various senior management positions at Allergan, Inc., including as vice president of strategic planning where he fostered licensing deals to build product pipelines. Earlier in his career, he was vice president of strategic marketing at Allergan Medical Optics, Inc. Mr. Largent also held positions of increasing responsibility in the marketing and sales departments at Allergan and Pharmacia Ophthalmics.

In addition to serving on Alimera's Board, Mr. Largent is on the board of directors of Tear Science, Inc., a privately held developer of diagnostic and therapeutic devices for the treatment of patients with dry eye disease. Mr. Largent earned a B.A. in chemistry and an M.B.A., both from the University of California, Irvine.


Peter J. Pizzo, III Independent Director Committee Chair for Audit Committee Member of Nominating and Governance Committee  
Vice President, Finance and Chief Financial Officer, Carticept Medical, Inc.

Peter Pizzo has been a member of our board of directors since April 2010. Since its formation in 2005, Mr. Pizzo has served as the Vice President, Finance and Chief Financial Officer of Carticept Medical, Inc., a private orthopedic medical device company, which he co-founded. From 2002 until its sale in 2005, Mr. Pizzo served as the Vice President, Finance and Chief Financial Officer of Proxima Therapeutics, Inc., a private medical device company that developed and marketed local radiation delivery systems for the treatment of solid cancerous tumors. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded global provider of biological products to life science companies, ultimately serving as Vice President of Finance and Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President of Administration and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals, and from 1992 until its sale in 1995, in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company, most recently as Treasurer. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University.


Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director
/* */